Abstract
Leflunomide has been shown to be very effective in preventing and curing several autoimmune animal diseases. Further, this agent is as effective as cyclosporin A in preventing the rejection of skin and kidney transplants in rats. Preliminary results from patients suffering from severe cases of rheumatoid arthritis demonstrated that clinical and immunological parameters could be improved with leflunomide therapy. Mode of action studies revealed that this substance antagonizes the proliferation inducing activity of several cytokines and is cytostatic for certain cell types. In this light, we could show that tyrosine phosphorylation of the RR-SRC peptide substrate and the autophosphorylation of the epidermal growth factor (EGF) receptor were, dose dependently, inhibited by leflunomide. EGF activates the intrinsic tyrosine kinase of its receptor, which stimulates the phosphorylation of a variety of peptides, the amino acid residue in all cases is tyrosine. These results indicate that much of leflunomide's activity could be due to the inhibition of tyrosine-kinase(s), which is an important general mechanism for the proliferation of various cell types. Thus, leflunomide, which is effective against autoimmune diseases and reactions leading to graft rejection, would seem to have a mode of action separating it from known immunosuppressive drugs.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
R. R. Bartlett, T. Mattar, U. Weithmann, H. Anagnostopulos, S. Popovic and R. Schleyerbach,Leflunomide (HWA 486): a novel immunorestoring drug. InTherapeutic approaches to inflammatory diseases (Eds. A. J. Lewis, N. S. Doherty and N. R. Ackerman), Elsevier Science Publishing Co., Inc. New York, pp. 215–228 (1989).
R. R. Bartlett and R. Schleyerbach,Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity I. Disease modifying action on adjuvant arthritis of the rat. Int J. Immunopharmac.7, 7–18 (1985).
R. R. Bartlett, R. X. Raiss, S. Popovic and R. Schleyerbach,Immunologic, histologic and ultrastructural studies in autoimmune MRL/1 mice. InArticular cartilage biochemistry (Eds. K. E. Kuettner, R. Schleyerbach and V. C. Hascall), pp. 391–412 (1986).
S. Popovic and R. R. Bartlett,Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents and Actions19, 313–314 (1986).
S. Popovic and R. R. Bartlett,The use of the murine chronic graft versus host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents and Actions21, 284–286 (1987).
R. D. Pasternak, N. S. Wadopian, R. N. Wright, P. Siminoff, J. A. Gylys and J. P. Buyniski,Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. Agents and Actions21, 241–243 (1987).
R. R. Bartlett, S. Popovic and R. X. Raiss,Development of autoimmunity in MRL/lpr mice and the effect of drugs on this murine disease. Scand. J. Rheumatol. Suppl.75, 290–299 (1988).
P. Hambleton and S. McMahon,Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. Agents and Actions29, 338–332 (1990).
T. Ogawa, M. Inazu, K. Gotoh and S. Hayashi,Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. Agents and Actions, in press (1990).
G. H. Thoenes, T. Sitter, K. H. Langer, R. R. Bartlett and R. Schleyerbach,Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int. J. Immunopharmac.11, 921–929 (1989).
R. Peper, B. Alvarez, C. Colombo and H. Schroder,The use of a standardized adjuvant arthritis assay to differentiate between anti-inflammatory and immunosuppressive agents. Proc. Soc. exp. Biol. Med.137, 506–512 (1971).
M. Hang, A. N. Theofilopoulos and F. J. Dixon,A spontaneous rheumatoid arthritis-like disease in MRL/1 mice. J. of Exp. Med.155, 1690–1701 (1982).
A. N. Theofilopoulos and F. J. Dixon,Etiopathogenesis of murine SLE. Immunological Review55, 179–216 (1981).
H. G. Fassbender,Joint destruction in various arthritic diseases. InArticular cartilage biochemistry (Eds. K. E. Kuettner, R. Schleyerbach and V. C. Hascall) pp. 371–389 (1986).
D. E. McFarlin, S. E. Blank, R. F. Kibler, S. McKneally and R. Shapira,Experimental allergic encephalomyelitis in the rat: response to encephalitogenic proteins and peptides. Sciences179, 478–483 (1973).
F. Mokhtarian, D. E. McFarlin and C. S. Raine,Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature309, 356–358 (1984).
H. Lassmann, G. Suchanek, K. Kitz, H. Stemberger, B. Schwerer and H. Bernheimer,Antibodies in the pathogenesis of demyelination in chronic relapsing EAE (cr-EAE). InExperimental allergic encephalomyelitis: a useful model for multiple sclerosis (Eds. E. C. Alvord, M. W. Kies and A. J. Suckling) pp. 165–170 Alan R. Liss, Inc., New York (1984).
E. C. Alvord,The challenge: How good a model of MS is EAE today? InExperimental allergic encephalomyelitis: a useful model for multiple sclerosis (Eds. E. C. Alvord, M. W. Kies and A. J. Suckling), pp. 3–5 Alan R. Liss, Inc., New York (1984).
G. H. Thoenes, T. Umscheid, T. Sitter and K. H. Langer,Cyclosporin A inhibits autoimmune experimental tubulointerstitial nephritis. Immunology Letters15, 301–306 (1987).
E. Gleichmann, E. H. Elven and J. P. W. Veen,A systemic lupus erythematosus (SLE)-like disease in mice induced by abnormal T-B cell cooperation. Preferential formation of autoantibodies characteristic of SLE. Eur. J. Immunol.12, 152–159 (1982).
C. S. Via, S. O. Sharrow and G. M. Shearer,Role of cytotoxic T lymphocytes in the prevention of Lupus-like disease occuring in a murine model of graft-vs-host disease. J. Immunol.139, 1840–1849 (1987).
R. C. Kuppers, T. Suiter, E. Gleichmann and N. R. Rose,The induction of organ-specific antibodies during the graft-vs-host reaction. Eur. J. Immunol.18, 161–166 (1988).
R. R. Bartlett,Cyclophosphamide. InThe pahrmacology of lymphocytes (Eds. M. A. Bray and J. Morley), pp. 453–469 Springer-Verlag, Berlin, Heidelberg, New York, (1988).
C. C. A. Küchle, G. H. Thoenes, K. H. Langer, H. U. Schorlemmer, R. R. Bartlett, and R. Schleyerbach,Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transp. Proc. (in press).
D. Bunjes, C. Hardt, M. Röllinghoff and H. Wagner,Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur. J. Immunol.11, 657–661 (1981).
R. R. Bartlett,Immunopharmacological profile of HWA 486, a novel isoxazol derivative- II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone or cyclosporin A. Int. J. Immunopharmac.8, 199–204 (1986).
M. Ennis and F. L. Pearce,Differential reactivity of isolated mast cells from the rat and guinea pig. Eur. J. Pharmacol.66, 339–343 (1980).
M. Ennis, F. L. Pearce and P. M. Weston,Some studies on the release of histamine from mast cells stimulated with polylsine. Br. J. Pharmacol.70, 329–332 (1980).
J. S. Goodwin,Regulation of T cell activation by leukotriene B4. Immunol. Res.5, 233–248 (1986).
A. Schimpel, L. Hübner, C. A. Wong and E. Wecker,Distinction between T helper cell replacing factor (TRF) and T cell growth factor (TCGF). Behring Inst. Mitt.67, 221–225 (1980).
R. Palacios, G. Henson, M. Steinmetz and J. P. Kearn,Interleukine-3 supports growth of mouse pre-B-cell clones in vitro. Nature309, 126–131 (1984).
M. Kimoto, V. Kindler, M. Higaki, C. Ody, S. Izui and P. Vassalli,Recombinant murine IL-3 fails to stimulate T or B lymphopoiesis in vivo, but enhances immune response to T cell-dependent antigens. J. Immunol.140, 1889–1894 (1988).
T. Kalland,Physiology of natural killer cells in vivo regulation of progenitors by interleukin 3. J. Immunol.139, 3671–3675 (1987).
W. E. Paul, J. Ohara,B cell stimulatory factor-1/interleukin 4. Ann. Rev. Immunol.5, 429–459 (1987).
H. Wagner, C. Hardt, K. Heeg, K. Pfizenmaier, W. Solbach, R. R. Bartlett, H. Stockinger and M. Röllinghoff,T-T cell interactions during cytotoxic T lymphocyte (CTL) responses: T cell derived helper factor (interleukin 2) as a probe to analyze CTL responsiveness and thymic maturation of CTL progenitors. Immunol. Rev.51, 215–255 (1980).
Y. Yarden and A. Ullrich,Growth factor receptor tyrosine kinases. Annu. Rev. Biochem.57, 443–478 (1988).
M. D. Waterfield,Epidermal growth factor and related molecules. Lancet, 1243–1246 (1989).
L. J. Pike,Assay of growth factor-stimulated tyrosine kinases using synthetic peptide substrates. Methods Enzamol.146, 353–363 (1987).
G. B. Mills, C. May, M. McGill, M. Fung, M. Baker, R. Sutherland and W. C. Greene,Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor β is tyrosine phosphorylated. J. Biol. Chem.265, 3561–3567 (1990).
S. L. Pelech, H. B. Paddon, D. L. Charest and B. S. Federspiel,IL-3-induced activation of protein kinases in the mast cell/megakaryocyte R6-Xe.4 line. J. Immunol.144, 1759–1766 (1990).
J. P. M. Evans, A. R. Mire-Sluis, A. V. Hoffbrand and R. G. Wickremasinghe,Binding of G-CSF, GM-CSF, tumor necrosis factor-α and τ-interferon to cell surface receptors on human myeloid leukemia cells triggers rapid tyrosine and serine phosphorylation of a 75-Kd protein. Blood75, 88–95 (1990).
B. Gasllis, K. S. Pricket, J. Jackson, J. Slack, K. Schooley, J. E. Sims, S. K. Dower,IL-1 induce rapid phosphorylation of the IL-1 receptor. J. Immunol.143, 3235–3240 (1989).
H. L. Goldberg, M. M. Viegas, B. L. Margolis, J. Schlessinger, and L. L. Skorecki,The tyrosine kinase activity of the epidermal-growth-factor receptor is necessary for phospholipase A 2 activation.Biochem. J. 267, 461–465 (1990).
B. L. Gruber, L. D. Kaufman, M. J. Marchese, W. Roth, A. P. Kaplan,Anti-IgE autoantibodies in systemic lupus erythematosus. Prevalence and biologic activity. Arthritis & Rheumatism31, 1000–1006 (1988).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bartlett, R.R., Dimitrijevic, M., Mattar, T. et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents and Actions 32, 10–21 (1991). https://doi.org/10.1007/BF01983301
Issue Date:
DOI: https://doi.org/10.1007/BF01983301